Compare Pfizer Inc (PFE) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs SkyWest Inc — how do they compare? Pfizer Inc trades at $27.93 (market cap $158.56B), while SkyWest Inc trades at $95.39 (market cap $3.75B). The key difference: Pfizer Inc is far larger — about 42.3× SkyWest Inc's market cap, and Pfizer Inc pays a 6.18% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and SkyWest Inc for 8 Days on average.
| PFE | SKYW | |
|---|---|---|
Market Cap | $158.56B | $3.75B |
Volume | 44,138,282 | 196,324 |
Sector | Health | Industrials |
52-Week High | $29.02 | $115.94 |
52-Week Low | $23.67 | $78.40 |
Typical Hold Time | 158 Days | 8 Days |
Enterprise Value | $210.06B | $5.54B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 9.6 and P/S of 0.94, while maintaining solid profitability with a 9.78% net income margin. Recent earnings have been mixed, with a Q1 2026 beat but a Q2 2026 miss. Positive developments include fleet modernization efforts and expanded flying agreements, though cost pressures remain a concern.
The investment case balances strong analyst support—58.82% recommend Buy with a $112 consensus target—against near-term technical weakness and earnings volatility. Upside potential exists from operational improvements and cash flow growth, but risks include execution on cost management and broader airline industry challenges. The stock presents a value opportunity for patient investors despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
